197 related articles for article (PubMed ID: 28983968)
21. [Susceptibility to 6-mercaptopurine toxicity related with NUDT15 and ABCC4 variants in Japanese childhood acute lymphoblastic leukemia].
Tanaka Y
Rinsho Ketsueki; 2017; 58(8):950-956. PubMed ID: 28883280
[TBL] [Abstract][Full Text] [Related]
22. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
23. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.
van der Werff Ten Bosch J; Suciu S; Thyss A; Bertrand Y; Norton L; Mazingue F; Uyttebroeck A; Lutz P; Robert A; Boutard P; Ferster A; Plouvier E; Maes P; Munzer M; Plantaz D; Dresse MF; Philippet P; Sirvent N; Waterkeyn C; Vilmer E; Philippe N; Otten J
Leukemia; 2005 May; 19(5):721-6. PubMed ID: 15744348
[TBL] [Abstract][Full Text] [Related]
24. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
[TBL] [Abstract][Full Text] [Related]
25. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
[TBL] [Abstract][Full Text] [Related]
26. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.
Chen L; Yan HX; Liu XW; Chen WX
Medicine (Baltimore); 2020 May; 99(18):e20082. PubMed ID: 32358392
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia.
Adamson PC; Zimm S; Ragab AH; Balis F; Steinberg SM; Kamen BA; Vietti TJ; Gillespie A; Poplack DG
Cancer Chemother Pharmacol; 1992; 30(2):155-7. PubMed ID: 1600597
[TBL] [Abstract][Full Text] [Related]
30. Prolonged
Mondelaers V; Suciu S; De Moerloose B; Ferster A; Mazingue F; Plat G; Yakouben K; Uyttebroeck A; Lutz P; Costa V; Sirvent N; Plouvier E; Munzer M; Poirée M; Minckes O; Millot F; Plantaz D; Maes P; Hoyoux C; Cavé H; Rohrlich P; Bertrand Y; Benoit Y;
Haematologica; 2017 Oct; 102(10):1727-1738. PubMed ID: 28751566
[TBL] [Abstract][Full Text] [Related]
31. Individualized Use of 6-Mercaptopurine in Chinese Children with ALL: A Multicenter Randomized Controlled Trial.
Zhou Y; Wang L; Sun LR; Zhang L; Wang HM; Liu XT; Yang F; Wu KL; Liang YL; Zhao BB; Zhuang Y; Fu JQ; Song C; Li Y; Wang LZ; Xu HJ; Gu Y; van den Anker J; Ju XL; Zhu XF; Zhao W
Clin Pharmacol Ther; 2024 Feb; 115(2):213-220. PubMed ID: 37753808
[TBL] [Abstract][Full Text] [Related]
32. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.
Lennard L; Welch J; Lilleyman JS
Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630
[TBL] [Abstract][Full Text] [Related]
33. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Henze G; v Stackelberg A; Eckert C
Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062
[TBL] [Abstract][Full Text] [Related]
34. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
35. Does intravenous 6-mercaptopurine decrease salvage after relapse in childhood acute lymphoblastic leukemia?
Mahoney DH; Camitta BM; Devidas M
Pediatr Blood Cancer; 2006 May; 46(5):660-1. PubMed ID: 16276523
[No Abstract] [Full Text] [Related]
36. [Acute lymphoblastic leukemia: a genomic perspective].
Jiménez-Morales S; Hidalgo-Miranda A; Ramírez-Bello J
Bol Med Hosp Infant Mex; 2017; 74(1):13-26. PubMed ID: 29364809
[TBL] [Abstract][Full Text] [Related]
37. [Research advances in pharmacogenomics of mercaptopurine].
Chen XX; Shen SH
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Sep; 19(9):1027-1033. PubMed ID: 28899477
[TBL] [Abstract][Full Text] [Related]
38. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood.
Toyoda Y; Manabe A; Tsuchida M; Hanada R; Ikuta K; Okimoto Y; Ohara A; Ohkawa Y; Mori T; Ishimoto K; Sato T; Kaneko T; Maeda M; Koike Ki; Shitara T; Hoshi Y; Hosoya R; Tsunematsu Y; Bessho F; Nakazawa S; Saito T
J Clin Oncol; 2000 Apr; 18(7):1508-16. PubMed ID: 10735899
[TBL] [Abstract][Full Text] [Related]
39. Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia.
Estlin EJ; Lowis SP; Hall AG
Br J Haematol; 2000 Jul; 110(1):29-40. PubMed ID: 10930977
[No Abstract] [Full Text] [Related]
40. Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
Escherich G; Zur Stadt U; Borkhardt A; Dilloo D; Faber J; Feuchtinger T; Imschweiler T; Jorch N; Pekrun A; Schmid I; Schramm F; Spohn M; Zimmermann M; Horstmann MA
Haematologica; 2022 May; 107(5):1026-1033. PubMed ID: 34348455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
